Blinded independent central review of progression in cancer clinical trials: Results from a meta-analysis
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Oncology
Reference33 articles.
1. Recommendations for the assessment of progression in randomised cancer treatment trials;Dancey;Eur J Cancer,2009
2. Onsite image evaluations and independent image blinded reads: close cousins or distant relatives?;Shamsi;J Clin Oncol,2009
3. Influence of an independent review committee on assessment of response rate and progression-free survival in phase III clinical trials;Tang;Ann Oncol,2010
4. Blinded independent central review of progression-free-survival in phase III clinical trials: important design element or unnecessary expense?;Dodd;J Clin Oncol,2008
5. Research outcomes and recommendations for the assessment of progression in cancer clinical trials from a PhRMA working group;Stone;Eur J Cancer,2011
Cited by 87 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial;The Lancet Respiratory Medicine;2024-05
2. Progression-free survival assessment by local investigators versus blinded independent central review in randomized clinical trials in metastatic breast cancer: A systematic review and meta-analysis;European Journal of Cancer;2024-01
3. Recent updates of clinical trials for colorectal cancer;Colorectal Cancer;2024
4. Optimizing disease progression assessment using blinded central independent review and comparing it with investigator assessment in the PRIMA/ENGOT-ov26/GOG-3012 trial: challenges and solutions;International Journal of Gynecologic Cancer;2023-11
5. Infigratinib for the Treatment of Metastatic or Locally Advanced Cholangiocarcinoma With Known FGFR2 Gene Fusions or Rearrangements;Cureus;2023-10-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3